Added Value of Interim FDG PET/CT in Resolving PSA-PSMA Discordance during PSMA-targeted Radioligand Therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 41490309.
- Also identified by DOI 10.1097/RLU.0000000000006260.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
PSMA-targeted radioligand therapy (RLT) is effective in metastatic castration-resistant prostate cancer, but interpretation is challenging when PSA rises despite apparent response on post-therapy 177 Lu-PSMA SPECT/CT. We present 2 patients with this PSA-PSMA discordance after 2 cycles: 177 Lu-PSMA post-therapy SPECT/CT showed a significant reduction in PSMA-derived tumor volume, yet PSA levels progressed. 18 F-FDG PET/CT performed after 2 cycles clarified disease status by revealing new hypermetabolic skeletal and visceral lesions, consistent with progression. PSMA-targeted RLT was discontinued early in both cases. 18 F-FDG PET/CT may resolve discordant PSA and PSMA findings and help prevent futile continuation of ineffective PSMA‑targeted RLT.
Medical subject headings
- Antigens, Surface
- Fluorodeoxyglucose F18
- Glutamate Carboxypeptidase II
- Molecular Targeted Therapy
- Positron Emission Tomography Computed Tomography
- Prostate-Specific Antigen